Cisplatin-based chemoradiotherapy remains a standard treatment for locally advanced head and neck squamous cell carcinoma (HNSCC), but cisplatin-induced ototoxicity is common, usually irreversible and inconsistently monitored.
✦ The floor
Discussion
Signed responses from readers of the wire.
Audiologists working with head and neck cancer patients should advocate for standardized ototoxicity monitoring protocols, as this systematic review highlights wide variation in current practice and a clear unmet need.
Standardizing ototoxicity monitoring for cisplatin-treated head and neck cancer patients could reduce preventable hearing loss and improve survivorship care across oncology settings.
- 01Systematic review synthesizes current evidence on cisplatin-induced hearing damage in head and neck cancer.
- 02Cisplatin ototoxicity (hearing damage from chemotherapy) is a well-documented but inconsistently monitored complication.
- 03No standardized monitoring protocol currently exists across clinical settings.
- 04Review calls for clinical guidelines to harmonize surveillance practices.
- 05Published in Current Oncology.
Cisplatin causes ototoxicity (hearing damage) in head and neck cancer patients.
studysupportedThere is currently no standardized monitoring protocol for cisplatin-induced ototoxicity in head and neck cancer.
studysupported- PMID
- 42930151
- DOI
- 10.3390/curroncol33100584.
- Journal
- Current Oncology
- Publication type
- review
- Evidence level
- 1a
- Population
- Head and neck cancer patients receiving cisplatin-based chemotherapy
- Intervention
- Cisplatin chemotherapy
Primary outcomes
Incidence and severity of ototoxicity; Adequacy of current monitoring protocols